Joshi J. Alumkal, M.D.
Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible changes in gene expression in cancer. His laboratory studies key chromatin modifying enzymes in cancer with an eye towards: 1) elucidating their function and role in transformation and disease progression and 2) targeting them with pharmacological agents in order to improve our ability to prevent and treat men with prostate cancer. Finally, his laboratory also focuses on the identification of biomarkers associated with prostate cancer development or aggressiveness.
"Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer,"
"Orteronel for the treatment of prostate cancer,"
"Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen,"
"Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation,"
"Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study,"